MultiBiotic™
Product description
MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance. MultiBiotic™ is an ARTG listed medicine and available in Pharmacies and HCP's in AU, NZ, SG and HK. Presently MultiBiotic™ is in Phase 1 clinical trials for chemotherapy induced mucositis and neutropenia. It is listed on the Australian New Zealand Clinical Trials Registry: ACTRN12618000927224
CLINICAL TRIAL: The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea: an exploratory end-point pilot study. ANZCTR: ACTRN12618000927224KEY
PUBLICATIONS: Thomsen M, Clarke S, Vitetta L 2018. The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Article in Press, Beneficial Microbes, 2018 online.
Palacios T, Vitetta L, Coulson S, Madigan C. D, Lam Y. Y, Manuel R, Briskey D, Hendy C, Kim J, Ishoey T, Soto-Giron M, Schott E. M, Toledo G, Caterson I. 2020. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study. Nutrients 2020, 12, 2041; doi:10.3390/nu12072041.
IP RIGHTS
Title: Probiotic compositions and uses thereof for treatment of obesity-related disorders Jurisdiction: Australia Application number: 2015258769 Filing date: 12 May 2015 Status: Under examination
Read more
CLINICAL TRIAL: The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea: an exploratory end-point pilot study. ANZCTR: ACTRN12618000927224KEY
PUBLICATIONS: Thomsen M, Clarke S, Vitetta L 2018. The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Article in Press, Beneficial Microbes, 2018 online.
Palacios T, Vitetta L, Coulson S, Madigan C. D, Lam Y. Y, Manuel R, Briskey D, Hendy C, Kim J, Ishoey T, Soto-Giron M, Schott E. M, Toledo G, Caterson I. 2020. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study. Nutrients 2020, 12, 2041; doi:10.3390/nu12072041.
IP RIGHTS
Title: Probiotic compositions and uses thereof for treatment of obesity-related disorders Jurisdiction: Australia Application number: 2015258769 Filing date: 12 May 2015 Status: Under examination
Specifications
Categories | Pharmaceutical Machinery & TechnologyBioavailability enhancement; Pharmaceutical PackagingDrug Delivery Systems; Finished Dosage Forms |
---|---|
Sales markets | Western Europe; Eastern Europe; Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central/South America |
Supplied from | Australia |
Products from other suppliers
❮
❯
-
VALSARIN 80/VALSARIN 160/VALSARIN 320
-
NURONORM
-
DERMOGEL NEW to treat inflammatory skin conditions
-
Anlitin (Levonorgestrel 1.5 mg) Tablet
-
Levocarnitine (LEKARNITIN) 1 G/5 ML SOLUTION FOR I.V. INJECTION
-
FOOD GRADE EPOXY COATING FOR INTERNAL POTABLE TANK PIPELINE - CLEAN TECH PW
-
Synatura Syrup
-
Ectoin® Allergy Eye Drops 2% - The innovation for treatment and prevention of allergic conjunctivitis symptoms
-
Kalmosan Skin Lotion
-
ComBE Five Pentavalent DTP-HepB-Hib
MultiBiotic™
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation